Introduction

In our last article we talked about why cancers can be so hard to treat, and how tumors are not the uniform masses most people picture. They are diverse, constantly evolving, and capable of adapting to the treatments designed to fight them.

That raises a really important question. If cancer can change over time, how do we keep track of it?

Traditionally, the answer has involved surgery or invasive procedures to collect tumor tissue. But a technology called liquid biopsy is changing that, and it is doing so through something as simple as a blood draw.

What Is a Liquid Biopsy?

As cancer cells grow and die, they shed tiny fragments of their genetic material into the bloodstream. These fragments, which can include DNA, RNA, and proteins, circulate through the body and can be picked up and analyzed from a blood sample.

A liquid biopsy is a test that does exactly that. The most studied form looks at what is called circulating tumor DNA (ctDNA), which is essentially small pieces of DNA that cancer cells release into the blood as they break down.

A helpful way to think about it: imagine reading a river downstream to understand what is happening further upstream. The material flowing past tells you something about where it came from, even if you never visit the source. That is essentially what a liquid biopsy does. It reads what the tumor has left behind in the bloodstream.

What Can It Actually Tell Us?

This is where it gets really interesting. Liquid biopsy is not just one thing. It has several different uses depending on where a patient is in their cancer journey.

For someone currently in treatment, tracking ctDNA levels over time can show whether the cancer is responding, staying stable, or starting to change in ways that might signal resistance developing. It gives clinicians a much more dynamic picture than a single scan taken every few months.

For someone who has finished treatment and is in a monitoring phase, rising ctDNA levels in the blood can sometimes pick up signs of the cancer returning before it shows up on imaging or causes any symptoms. That earlier warning can make a real difference to what options are available and how quickly clinicians can act.

Why Is This Such a Big Deal?

Getting a traditional tissue sample means a surgeon has to physically remove a piece of the tumor. That is invasive, sometimes risky depending on where the tumor is located, and obviously not something that can be done repeatedly every few weeks to track how things are progressing. It also only captures what the tumor looked like at that one moment in time.

A blood draw changes the equation entirely. It is low risk, can be done repeatedly, and gives clinicians a way to watch how the cancer is evolving in something close to real time rather than taking periodic snapshots months apart.

For patients, that can mean fewer invasive procedures, earlier detection of problems, and treatment decisions that adapt as the cancer changes rather than being locked in based on what things looked like at diagnosis.

The Honest Limitations

Liquid biopsy is exciting, but it is worth being clear about where it currently falls short.

Not all tumors shed enough genetic material into the bloodstream to be reliably detected. For some cancer types and some patients, the levels of ctDNA in the blood are simply too low to give a clear signal. A negative result does not always mean the cancer is gone or stable, which is an important thing to understand before reading too much into a result. And beyond detection sensitivity, it is also worth being clear about what liquid biopsy is and is not suited for.

There is also the question of what liquid biopsy is actually best suited for, because not all applications are equal. It works well for monitoring residual tumour after surgery, tracking treatment response over time, and potentially for early detection depending on how the test is designed. Where it falls short is in characterising the biology of the tumour itself, determining prognosis, or figuring out which treatments are most likely to work. For those questions, a direct tissue sample that can be fully analysed is still the gold standard. Liquid biopsy is a powerful monitoring tool, but it is not a replacement for the deeper biological profiling that guides treatment selection in the first place. Used in the right context, it adds a layer of insight that was simply not possible before.

Where Things Are Heading

Liquid biopsy is one of the fastest moving areas in precision oncology right now. Tests are becoming more sensitive, more widely available, and more affordable. Researchers are also exploring its use in early cancer detection, looking for ctDNA in the blood of people who have not yet been diagnosed, with the hope of catching cancers at a stage when they are far easier to treat.

There is also growing interest in looking beyond just DNA, to RNA and proteins that tumors shed into the blood, which can give an even richer picture of what the cancer is doing at a biological level.

Conclusion

Liquid biopsy is not perfect, but it is a genuinely important step forward in how we monitor and understand cancer. By giving clinicians a clearer, more dynamic picture of what a tumor is doing through something as simple as a blood test, it is helping to make cancer care more responsive, more personalized, and less burdensome for patients.

In our next article we will look at something that is changing how we think about cancer altogether. For decades, research focused almost entirely on the tumor cells themselves. But it turns out the environment surrounding those cells, including immune cells and blood vessel cells, plays a huge role in how cancer grows and spreads. And increasingly, those surrounding cells are becoming targets for treatment too.